Evidence map›Paper›PMID 26308708›Full record

Trial reportJournal of bone and mineral metabolism2016

Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.

Yoshiya Tanaka, Hiroko Mori, Takatoshi Aoki, Tatsuya Atsumi, Yutaka Kawahito, Hisanori Nakayama, Shigeto Tohma, Yuji Yamanishi, Hitoshi Hasegawa, Kazuhide Tanimura and 6 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of bone and mineral metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Advances in treatment of glucocorticoid-induced osteoporosis.Current opinion in endocrinology, diabetes, and obesity · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
Hiroko MoriFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
Takatoshi AokiDepartment of Radiology, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Tatsuya AtsumiDepartment of Internal Medicine, Hokkaido University, Sapporo, Japan.
Yutaka KawahitoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hisanori NakayamaDepartment of Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, Japan.
Shigeto TohmaDepartment of Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, Japan.
Yuji YamanishiDepartment of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan.
Hitoshi HasegawaDepartment of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Kazuhide TanimuraHokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan.
Nobuo NegoroClinical Immunology and Rheumatology, Osaka City University, Osaka, Japan.
Yukitaka UekiDepartment of Internal Medicine, Sasebo Central Hospital, Nagasaki, Japan.
Atsushi KawakamiUnit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Katsumi EguchiUnit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kazuyoshi SaitoFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan.
Yosuke OkadaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. y-okada@med.uoeh-u.ac.jp.
University of Occupational and Environmental Health Japan · JPNagasaki University · JPNational Sagamihara Hospital · JPEhime University · JPHokkaido University · JPInstitute for Rheumatic Diseases (Japan) · JPKyoto Prefectural University of Medicine · JPOsaka City University · JPSasebo City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a prospective multicenter study to assess early changes in the dynamics of bone metabolism in patients with systemic connective tissue diseases following commencement of high-dose glucocorticoid therapy and the benefits of early treatment with bisphosphonate and vitamin D analogue. The subjects of this randomized controlled trial were 106 female patients with systemic connective tissue diseases treated for the first time with glucocorticoids at doses equivalent to prednisolone ≥20 mg/day (age ≥ 18 years). One week after initiation of glucocorticoid therapy, patients were randomly assigned to treatment with alfacalcidol at 1 μg/day (n = 33), alendronate 35 mg/week (n = 37), and alfacalcidol plus alendronate (n = 36). The primary endpoints were changes in lumbar spine bone density at 6 months of treatment and the frequency of bone fracture at 12 months. Commencement of glucocorticoid therapy was associated with a rapid and marked bone resorption within 1 week. The combination of alfacalcidol and alendronate administered after the first week of glucocorticoid therapy halted the pathological processes affecting bone metabolism, increased bone density, and reduced the incidence of bone fracture over a period of 12 months. Taken together, the use of the combination of alfacalcidol and alendronate improved bone metabolism, increased bone density, and significantly reduced the incidence of bone fracture during 1-year high-dose glucocorticoid therapy.

Indexed as

Fractures, BoneGlucocorticoidsOsteoporosisRheumatic DiseasesAdolescentAdultAgedAged, 80 and overAlendronateBone DensityFemaleHumansHydroxycholecalciferolsMiddle AgedAlendronatealfacalcidolGlucocorticoidsHydroxycholecalciferolsAlendronateAutoimmune diseaseGlucocorticoidOsteoporosis

Identifiers

PMID26308708
OpenAlexW2164910670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.